<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04383210</url>
  </required_header>
  <id_info>
    <org_study_id>ELVCAP-001-01</org_study_id>
    <nct_id>NCT04383210</nct_id>
  </id_info>
  <brief_title>Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors</brief_title>
  <official_title>CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elevation Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elevation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, international, multi-center, Phase 2 study in adult patients&#xD;
      with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene&#xD;
      fusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The primary objective of this study is to determine the overall objective response rate (ORR) by independent radiologic review to single agent seribantumab in patients with NRG1 gene fusion positive advanced cancer according to RECIST 1.1</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Locally Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Bile Duct Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Uterine Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.&#xD;
Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.&#xD;
Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.&#xD;
Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seribantumab</intervention_name>
    <description>Anti-HER3 monoclonal antibody</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for participation in the study, patients must meet the following inclusion&#xD;
        criteria:&#xD;
&#xD;
          -  Locally-advanced or metastatic solid tumor with an NRG1 gene fusion identified through&#xD;
             molecular assays, such as PCR, NGS (RNA or DNA) or FISH, by a CLIA-certified or&#xD;
             similarly accredited laboratory&#xD;
&#xD;
          -  Availability of fresh or archived FFPE tumor sample to be submitted to a central&#xD;
             laboratory for confirmation of NRG1 gene fusion status&#xD;
&#xD;
          -  Patients should have received a minimum of one prior standard therapy appropriate for&#xD;
             their tumor type and stage of disease, progressed or been nonresponsive to these&#xD;
             available therapies, with no further available curative therapy options&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  ECOG performance status (PS) 0, 1 or 2&#xD;
&#xD;
          -  Patients must have at least one measurable extra-cranial lesion as defined by RECIST&#xD;
             v1.1&#xD;
&#xD;
          -  Adequate hepatic function defined as:&#xD;
&#xD;
          -  Serum AST and serum ALT &lt; 2.5 × upper limit of normal (ULN), or AST and ALT &lt; 5 × ULN&#xD;
             if liver function abnormalities due to underlying malignancy&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 ULN. Subjects with a known history of Gilberts Disease and an&#xD;
             isolated elevation of indirect bilirubin are eligible&#xD;
&#xD;
          -  Adequate hematologic status, defined as:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.5 × 109/L not requiring growth factor support for&#xD;
             at least 7 days prior to Screening, and&#xD;
&#xD;
          -  Platelet count ≥100.0×109/L not requiring transfusion support for at least 7 days&#xD;
             prior to Screening&#xD;
&#xD;
          -  Able to provide informed consent or have a legal representative able and willing to do&#xD;
             so&#xD;
&#xD;
          -  Ability to comply with outpatient treatment, laboratory monitoring, and required&#xD;
             clinic visits for the duration of study participation&#xD;
&#xD;
          -  Willingness of men and women of reproductive potential to observe conventional and&#xD;
             effective birth control for the duration of treatment and for 3 months following study&#xD;
             completion; this may include barrier methods such as condom or diaphragm with&#xD;
             spermicidal gel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known, actionable oncogenic driver mutation other than NRG1 fusion where available&#xD;
             standard therapy is indicated&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Prior treatment with ERBB3/HER3 directed therapy (Cohort 1 only)&#xD;
&#xD;
          -  Prior treatment with pan-ERBB or any ERBB/HER2/HER3 directed therapy (Cohort 1 only)&#xD;
&#xD;
          -  Symptomatic or untreated brain metastases (Note: Patients with asymptomatic brain&#xD;
             metastases treated with radiation or surgery and without evidence of progression by&#xD;
             imaging at screening are eligible to participate in the study. Patients requiring&#xD;
             ongoing corticosteroids to treat brain metastases will not be eligible).&#xD;
&#xD;
          -  Received other investigational agent or anticancer therapy within 28 days prior to&#xD;
             planned start of seribantumab or 5 half-lives, whichever is shorter&#xD;
&#xD;
          -  Prior to initiation of seribantumab treatment, patients must have recovered from&#xD;
             clinically significant toxicities from prior anticancer or investigational therapy&#xD;
&#xD;
          -  Any other active malignancy requiring systemic therapy&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of seribantumab or previous CTCAE&#xD;
             grade 3 or higher hypersensitivity reactions to fully human monoclonal antibodies&#xD;
&#xD;
          -  Clinically significant cardiac disease, including symptomatic congestive heart&#xD;
             failure, unstable angina, acute myocardial infarction within 12 months of planned&#xD;
             first dose, or unstable cardiac arrhythmia requiring therapy (including torsades de&#xD;
             pointes)&#xD;
&#xD;
          -  Active uncontrolled systemic bacterial, viral, or fungal infection&#xD;
&#xD;
          -  Patients who are not appropriate candidates for participation in this clinical study&#xD;
             for any other reason as deemed by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>VP, Clinical Operations</last_name>
    <phone>716-371-1125</phone>
    <email>clinical@elevationoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VP, Medical Affairs</last_name>
    <phone>716-371-1125</phone>
    <email>medicalaffairs@elevationoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddy Yang, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Tsai, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-698-0300</phone>
    </contact>
    <investigator>
      <last_name>Haresh Jhangiani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Nguyen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Reckamp, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viola Zhu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tejas Patil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Hematology Consultants</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal Misleh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Socinski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Haura, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Cancer And Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Westin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hawaii Cancer Care</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melvin Palalay, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Chae, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-726-5130</phone>
    </contact>
    <investigator>
      <last_name>Jessica Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>313-916-3721</phone>
      <email>CTOResearch@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Shirish M. Gadgeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Minnesota CCOP</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Anderson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Saiama N. Waqar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yungpo B Su, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Balasz Halmos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Carrizosa, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Otterson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shivaani Kummar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Moore</last_name>
      <email>Misty.Moore@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>David R. Spigel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasir Elamin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Disean Kendall, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander I. Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>253-428-8750</phone>
    </contact>
    <investigator>
      <last_name>Frank M. Senecal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-323-8942</phone>
    </contact>
    <investigator>
      <last_name>Mark E. Burkard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parneet Cheema, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NRG1</keyword>
  <keyword>Neuregulin 1</keyword>
  <keyword>Gene fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

